Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial

PLoS One. 2018 Jan 9;13(1):e0190118. doi: 10.1371/journal.pone.0190118. eCollection 2018.

Sanjiv M Baxi^{1

2}, Eric Vittinghoff³, Peter Bacchetti³, Yong Huang⁴, Kata Chillag⁵, Ryan Wiegand⁶, Peter L Anderson⁷, Robert Grant^{1

8

9}, Ruth M Greenblatt^{1

3

10}, Susan Buchbinder^{1

3

11}, Monica Gandhi¹, Albert Y Liu^{1

11}

¹ Department of Medicine, University of California, San Francisco, California, United States of America.
² School of Public Health, Division of Epidemiology, University of California, Berkeley, California, United States of America.
³ Department of Epidemiology and Biostatistics, University of California, San Francisco, California, United States of America.
⁴ Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, United States of America.
⁵ Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Atlanta, Georgia, United States of America.
⁶ Division of Parasitic Diseases and Malaria, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
⁷ Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, United States of America.
⁸ Gladstone Institutes, San Francisco, California, United States of America.
⁹ San Francisco AIDS Foundation, San Francisco, California, United States of America.
¹⁰ Department of Clinical Pharmacy, University of California, San Francisco, California, United States of America.
¹¹ San Francisco Department of Public Health, San Francisco, California, United States of America.

Abstract

Clinical Trials.gov NCT00131677.